- Language: English
- 302 Pages
- Published: November 2012
- Region: Global
China Diabetes Market Analysis
- Published: July 2011
- Region: China
- 50 Pages
- RNCOS E-Services Private Limited
Diabetes has emerged as one of the most common diseases in China, affecting over 92 Million people at the end of 2010. The country has a significant share in the diabetes market globally with a major share of diabetics in the country affected with type-II diabetes. Factors, such as incidence of diabetes associated with Western diets and an aging population has contributed to such a stupendous escalation in the diabetes population in China. Consequently, the oral diabetes drug market of China is anticipated to grow at a CAGR of around 5.3% during 2012 - 2014.
This report has also found that, one of the main factors for the growth of the market is the entry of numerous foreign pharmaceutical giants in the diabetes market. The main factor for the interest of foreign players in the country’s diabetes market is the huge customer base, cheap labor and land cost provided by the country. Besides, increasing prevalence of obesity has played an important role in surging the number of diabetic patients in the country, which in turn, has fuelled the diabetes market in the country.
It has been believed that, diabetes will have major implications for people’s health and life expectancy. It will result in out-of-control China healthcare costs, placing growing strain on the budgets of families, employers, states, and the government. Studies carried out by WHO have shown that, China will lose around US$ 557.7 Billion of national income to diabetes and cardiovascular disease during 2005 - 2015.
“China Diabetes Market Analysis” highlights the Chinese diabetes market by segmenting it into – oral diabetic drug market, insulin drug market, insulin delivery devices market, and glucose monitoring market. Each of these segments have been thoroughly studied and analyzed in the report. Moreover, the report provides an overview of the patient profile and cost implications of diabetes in the country, which will help clients in identifying the future demand scenario.
The report studies the current development process and its effects on various segments of the industry. The research contains exhaustive information regarding the market players, government initiatives, and patient profile that will help clients in formulating market strategies and assess opportunity areas in the Chinese diabetes market. SHOW LESS READ MORE >
1. Analyst View
2. Research Methodology
3. Patient Profile Analysis
4. Cost Implications
5. Market Drivers and Trends
5.1 Rising Prevalence of Obesity
5.2 Increasing Investment from Global Giants
5.3 Consolidation of the Industry
5.4 Emerging Insulin Delivery Devices
5.4.1 Oral Insulin
5.4.2 Insulin Jet Injectors
6. Diabetes Drugs Market
6.1 Oral Diabetic Drugs Market
6.1.1 By Drugs
6.2 Insulin Drugs Market
6.2.1 By Players
7. Insulin Delivery Devices Market
7.1 Insulin Pump
7.2 Insulin Pen
7.3 Insulin Syringes
8. Glucose Monitoring Devices Market
8.1 Self Monitoring Blood Glucose (SMBG) Devices
9. Government Regulations and Initiatives
10. Key Players
10.1 Novo Nordisk
10.2 Eli Lilly
10.5 Merck & Co.
10.6 Tianjin Takeda Pharmaceuticals Co Ltd
10.7 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.8 Wanbang Biopharmaceuticals
List of Figures:
Figure 3-1: Prevalence of Diabetes (%), 2010 & 2030
Figure 3-2: Prevalence of Impaired Glucose Tolerance (%), 2010 & 2030
Figure 3-3: Number of Diabetic Population (Million), 2010 & 2030
Figure 4-1: India & China - National Income Loss by Diabetes and Cardiovascular Diseases (Billion US$), 2005 to 2015
Figure 6-1: Oral Diabetic Drugs Market (Billion US$), 2010-2014
Figure 6-2: Insulin Drugs Market (Billion US$), 2010-2014
Figure 6-3: Insulin Market Share by Player (2010)
Figure 7-1: Insulin Pump Market (Million US$), 2010-2014
Figure 7-2: Insulin Pen Market (Million US$), 2010-2014
Figure 7-3: Insulin Syringes Market (Billion US$), 2010-2014
Figure 8-1: SMBG Devices Market (Million US$), 2010-2014
- Novo Nordisk
- Eli Lilly
- Merck & Co.
- Tianjin Takeda Pharmaceuticals Co Ltd
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Wanbang Biopharmaceuticals